Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6874813 in Advanced Solid Tumors
NCT02558140Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2015
- Primary completion
- Nov 2017
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of RO6874813 in solid tumor and sarcoma (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 10 more. Started Oct 2015; status: completed.
02
Drugs
RO6874813
03
Conditions
solid tumorsarcoma
Beyond the preview
Go deeper on NCT02558140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558140.